The Innovative nanoMedicines for Prenatal and Cancer Therapy Lab is at the interface of nanotechnology, engineering, and medicine to develop drug delivery platforms to study and treat disease. We engineer nanoparticles for applications in women’s health, including cancers and prenatal therapy.
Principal Investigator
dr. Rachel Riley, PhD
assistant professor
Henry M. Rowan Department of Biomedical Engineering
Rowan University
e-mail: rileyr@rowan.edu
Research
-
Engineering Nanomaterials to Study and Treat Disease
-
Drug Delivery in Maternal-Fetal Medicine
-
Nanotechnology for Cancers
Key Publications
-
Ionizable lipid nanoparticles for in utero mRNA delivery
Science Advances (2021)
-
Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy
Advanced Drug Delivery Reviews (2020)
-
Evaluating the Mechanisms of Light-Triggered siRNA Release from Nanoshells for Temporal Control Over Gene Regulation
Nano Letters (2018)
Positions
The Riley lab is starting up, and we are excited to grow! We are looking for undergraduate students, graduate students (including Ph.D., M.D., and M.D./Ph.D. students), and postdoctoral researchers to be part of the team.
Our research is interdisciplinary and spans chemical synthesis, molecular biology, and nanomaterials engineering, so we are looking for talented researchers interested in gaining experience in each of these areas.
If you are interested, please e-mail Dr. Riley (rileyr@rowan.edu) with your research experiences and interests, as well as a copy of your CV . We hope to hear from you soon!
Pledge for Diversity and Inclusion
We believe that diversity in the lab drives creativity, ambition, and inspiration both in research and in life. We strive to build an inclusive environment for all trainees, and we embrace each others' differences and experiences to form a community that cares about the well-being and success of all trainees. This is why we have taken a diversity pledge.
